Status:
COMPLETED
MK0524A Bioequivalence Study (0524A-059)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Dyslipidemia
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study will evaluate the definitive bioequivalence of tablets of MK0524A (1000 mg Extended Release (ER) Niacin/ 20 mg laropiprant) from two sources.
Eligibility Criteria
Inclusion
- Subject is in good health
- Subject is willing to follow all study guidelines
Exclusion
- Subject has or has a history of any disease or condition that might confound the results of the study or make participation unsafe
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT00944645
Start Date
October 1 2006
End Date
January 1 2007
Last Update
June 19 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.